drugset / Trial / NCT00527657
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest safe dose of lomustine (CCNU, CeeNUTM) that can be given with temozolomide (TemodarTM) and thalidomide (ThalomidTM) in the treatment of metastatic melanoma that has spread to the brain. The safety and effectiveness of this combination therapy will also be studied.
Timeline
- Start
- 2006-02-09
- Primary completion
- 2012-02-02
- Completion
- 2012-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lomustine | Small molecule | 30 mg/m2 | Oral |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |
| Subject | Thalidomide | Other / unclassified | 200 mg/m2 | Oral |